EU filing for CPP's familial adenomatous polyposis drug
US private biotech Cancer Prevention Pharmaceuticals has filed a marketing application in Europe for CPP-1X/sul, a preventative treatment for patients with familial adenomatous polyposis (FAP).
FAP is a rare genetic disease that, if left untreated, causes colorectal cancer in nearly 100% of patients.
Read more: https://bit.ly/2ChZ6eZ
FAP is a rare genetic disease that, if left untreated, causes colorectal cancer in nearly 100% of patients.
Read more: https://bit.ly/2ChZ6eZ
